New treatment options for late na current, arrhythmias, and diastolic dysfunction

Current Heart Failure Reports

Volumn 9, Issue 3, 2012, Pages 183-191

  Maier, Lars S ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Action potential duration; Arrhythmias; Atrial fibrillation; Diastolic dysfunction; Heart failure; Heart failure with preserved ejection fraction; Intracellular Na overload; IntracellularCa overload; Late Na current inhibition; LateNa current; Ranolazine; Therapy; Treatment; Ventricular arrhythmias

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALCIUM; DRONEDARONE; ENALAPRIL; METOPROLOL; RANOLAZINE; RYANODINE; SODIUM; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL; ACETANILIDE DERIVATIVE; ANTIARRHYTHMIC AGENT; CARDIOVASCULAR AGENT; CATION; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; SODIUM CHANNEL NAV1.5;

ARTICLE; CALCIUM CELL LEVEL; DIASTOLE; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DRUG EFFICACY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE POTENTIAL; HUMAN; IC 50; LONG QT SYNDROME; NONHUMAN; SARCOPLASMIC RETICULUM; SODIUM CELL LEVEL; SODIUM CURRENT; SUPRAVENTRICULAR TACHYCARDIA; TORSADE DES POINTES; ACTION POTENTIAL; DRUG EFFECT; HEART CONTRACTION; METABOLISM; REVIEW;

ACETANILIDES; ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; CALCIUM; CARDIOVASCULAR AGENTS; CATIONS; DIASTOLE; ENZYME INHIBITORS; HEART FAILURE; HEART FAILURE, DIASTOLIC; HUMANS; MYOCARDIAL CONTRACTION; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; PIPERAZINES; SODIUM; SODIUM-CALCIUM EXCHANGER;

EID: 84871866172     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0099-3     Document Type: Article

References (68)

1. Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res. 1992;71:1231-41.
2. Maier LS, Pieske B, Allen D Influence of stimulation frequency on [Na+]i and contractile function in Langendorff-perfused rat heart. Am J Physiol 1997;H1246-54
3. Pieske B, Maier LS, Piacentino 3rd V, Weisser J, Hasenfuss G, Houser S. Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation. 2002;106:447-53. (Pubitemid 34803689)
4. Maltsev VA, Undrovinas A. Late sodium current in failing heart: friend or foe? Prog Biophys Mol Biol. 2008;96:421-51. (Pubitemid 351635619)
5. Wagner S, Maier LS. Modulation of cardiac Na and Ca currents by CaM and CaMKII. J Cardiovasc Electrophysiol. 2006;17 Suppl 1: S26-33.
6. Xi Y, Wu G, Yang L, Han K, Du Y, Wang T, Lei X, Bai X, Ma A. Increased late sodium currents are related to transcription of neuronal isoforms in a pressure-overload model. Eur J Heart Fail. 2009;11:749-57.
7. Fredj S, Lindegger N, Sampson KJ, Carmeliet P, Kass RS. Altered Na+ channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3 myocytes. Circ Res. 2006;99:1225-32. (Pubitemid 44808659)
8. Huang B, El-Sherif T, Gidh-Jain M, Qin D, El-Sherif N. Alterations of sodium channel kinetics and gene expression in the postinfarction remodeled myocardium. J Cardiovasc Electrophysiol. 2001;12:218-25. (Pubitemid 32171514)
9. Ju YK, Saint DA, Gage PW. Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol. 1996;497:337-47. (Pubitemid 26418103)
10. Maltsev VA, Silverman N, Sabbah HN, Undrovinas AI. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. Eur J Heart Fail. 2007;9:219-27. (Pubitemid 46330143)
11. Sossalla S, Kallmeyer B, Wagner S, Mazur M, Maurer U, Toischer K, Schmitto JD, Seipelt R, Schondube FA, Hasenfuss G, Belardinelli L, Maier LS. Altered Na+ currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol. 2010;55:2330-42. This is the first report in human myocardium showing altered Na currents in atrial fibrillation and the beneficial effects of ranolazine on arrhythmogenesis. The RAFFAELLO study mainly results from this report.
12. Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schondube FA, Tirilomis T, Tenderich G, Hasenfuss G, Belardinelli L,Maier LS. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol. 2008;45:32-43.
13. Makielski JC, Farley AL. Na(+) current in human ventricle: implications for sodium loading and homeostasis. J Cardiovasc Electrophysiol. 2006;17 Suppl 1:S15-20.
14. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92 Suppl 4:iv6- iv14.
15. Wagner S, Seidler T, Picht E, Maier LS, Kazanski V, Teucher N, Schillinger W, Pieske B, Isenberg G, Hasenfuss G, Kogler H. Na+- Ca2+ exchanger overexpression predisposes to reactive oxygen species-induced injury. Cardiovasc Res. 2003;60:404-12. (Pubitemid 37412374)
16. Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC. A comparison between ranolazine and CVT- 4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther. 2007;321:213-20. (Pubitemid 46456960)
17. Brandes R, Maier LS, Bers DM. Regulation of mitochondrial [NADH] by cytosolic [Ca2+] and work in trabeculae from hypertrophic and normal rat hearts. Circ Res. 1998;82:1189-98. (Pubitemid 28311126)
18. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309-16. (Pubitemid 38101603)
19. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AA. Antiischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375-82. (Pubitemid 38496341)
20. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904-10. (Pubitemid 39136212)
21. Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther. 2006;318:214-22.
22. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol. 2006;17 Suppl 1: S169-77.
23. Wang GK, Calderon J, Wang SY. State- And use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine. Mol Pharmacol. 2008;73:940-8. (Pubitemid 351397898)
24. Beyder A, Strege PR, Reyes S, Bernard CE, Terzic A, Makielski J, Ackerman MJ, Farrugia G Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel NaV1.5: a novel mechanism of drug action. Circulation. 2012;125:2698-2706. This is the first report showing a novel mechanism of how Na channel scan be activated (ie, by mechanosensitivity) and how ranolazine may decrease this mechanism.
25. von Lewinski D, Stumme B, Maier LS, Luers C, Bers DM, Pieske B. Stretch-dependent slow force response in isolated rabbit myocardium is Na+ dependent. Cardiovasc Res. 2003;57:1052-61. (Pubitemid 36324610)
26. Lovelock JD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG, Taglieri DM, Gu L, Kumar P, Pokhrel N, Zeng D, Belardinelli L, Sorescu D, Solaro RJ, Dudley Jr. SC. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res. 2012;110(6):841-50.
27. Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther. 1994;8:741- 7. (Pubitemid 24376754)
28. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008;19:1289-93.
29. Figueredo VM, Pressman GS, Romero-Corral A, Murdock E, Holderbach P, Morris DL. Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina. J Cardiovasc Pharmacol Ther. 2011;16:168-72. This is the first clinical report in patients showing improved echocardiographic parameters of left ventricular function in response to ranolazine.
30. Morrow DA, Scirica BM, Sabatine MS, de Lemos JA, Murphy SA, Jarolim P, Theroux P, Bode C, Braunwald E. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol. 2010;55:1189-96.
31. Sabbah HN, Chandler MP, Mishima T, Suzuki G, Chaudhry P, Nass O, Biesiadecki BJ, Blackburn B, Wolff A, Stanley WC. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail. 2002;8:416-22. (Pubitemid 36055744)
32. Rastogi S, Sharov VG, Mishra S, Gupta RC, Blackburn B, Belardinelli L, Stanley WC, Sabbah HN. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol. 2008;295:H2149-55.
33. Jacobshagen C, Belardinelli L, Hasenfuss G, Maier LS. Ranolazine for the treatment of heart failure with preserved ejection fraction: Background, aims, and design of the RALI-DHF study. Clin Cardiol. 2011;34:426-32.
34. Sossalla S, Fluschnik N, Schotola H, Ort KR, Neef S, Schulte T, Wittkopper K, Renner A, Schmitto JD, Gummert J, El-Armouche A, Hasenfuss G, Maier LS. Inhibition of elevated Ca2+/calmodulin- dependent protein kinase II improves contractility in human failing myocardium. Circ Res. 2010;107:1150-61.
35. Sossalla S, Maurer U, Schotola H, Hartmann N, DidieM, Zimmermann W, Jacobshagen C, Wagner S, Maier LS (2011) Diastolic dysfunction and arrhythmias caused by overexpression of CaMKIIdC can be reversed by inhibition of late Na+ current. Basic Res Cardiol 263-272
36. Wagner S, Dybkova N, Rasenack EC, Jacobshagen C, Fabritz L, Kirchhof P, Maier SK, Zhang T, Hasenfuss G, Brown JH, Bers DM, Maier LS. Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels. J Clin Invest. 2006;116:3127-38. (Pubitemid 44878627)
37. Grandi E, Puglisi JL, Wagner S, Maier LS, Severi S, Bers DM. Simulation of Ca-calmodulin-dependent protein kinase II on rabbit ventricular myocyte ion currents and action potentials. Biophys J. 2007;93:3835-47. (Pubitemid 350223802)
38. Wagner S, Ruff HM, Weber SL, Bellmann S, Sowa T, Schulte T, Grandi E, Bers DM, Backs J, Belardinelli L, Maier LS. Reactive oxygen species-Activated Ca/Calmodulin Kinase IId is required for late INa augmentation leading to cellular Na and Ca overload. Circ Res. 2011;108:555-65.
39. Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006;41:1031- 8. (Pubitemid 44791334)
40. Gralinski MR, Black SC, Kilgore KS, Chou AY, McCormack JG, Lucchesi BR. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res. 1994;28:1231- 7. (Pubitemid 24264731)
41. Wu Y, Song Y, Belardinelli L, Shryock JC. The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-Lcarnitine to increase late INa and cause ventricular diastolic dysfunction. J Pharmacol Exp Ther. 2009;330:550-7.
42. Maruyama K, Hara A, Hashizume H, Ushikubi F, Abiko Y. Ranolazine attenuates palmitoyl-L-carnitine-induced mechanical and metabolic derangement in the isolated, perfused rat heart. J Pharm Pharmacol. 2000;52:709-15. (Pubitemid 30410085)
43. Sag CM, Wadsack DP, Khabbazzadeh S, Abesser M, Grefe C, Neumann K, Opiela MK, Backs J, Olson EN, Brown JH, Neef S, Maier SK, Maier LS. Calcium/calmodulin-dependent protein kinase II contributes to cardi-Ac arrhythmogenesis in heart failure. Circ Heart Fail. 2009;2:664-75.
44. Cheng H, Lederer WJ. Calcium sparks. Physiol Rev. 2008;88:1491-545.
45. Song Y, Shryock JC, Belardinelli L. An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol. 2008;294:H2031-9.
46. Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther. 2004;310:599-605. (Pubitemid 38992327)
47. Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-Arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004;44:192- 9. (Pubitemid 38982162)
48. Dhalla AK, Wang WQ, Dow J, Shryock JC, Belardinelli L, Bhandari A, Kloner RA. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2009;297:H1923-9.
49. Morita N, Lee JH, Xie Y, Sovari A, Qu Z, Weiss JN, Karagueuzian HS. Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. J Am Coll Cardiol. 2011;57:366-75. In this report, pacing-induced re-entrant ventricular fibrillation and early afterdepolarization-mediated multifocal ventricular fibrillation was shown in perfused rat hearts.
50. Lemoine MD, Duverger JE, Naud P, Chartier D, Qi XY, Comtois P, Fabritz L, Kirchhof P, Nattel S. Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model. Cardiovasc Res. 2011;92:67-72. This report shows for the first time in a genetic mouse model of long QT 3 atrial fibrillation and how ranolazine improves arrhythmogenesis.
51. Antzelevitch C, Sicouri S, Litovsky SH, Lukas A, Krishnan SC, Di Diego JM, Gintant GA, Liu DW. Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ Res. 1991;69:1427- 49.
52. Zygmunt A, Goodrow R, Antzelevitch C (2000) I NaCa contributes to electrical heterogeneity within the canine ventricle. Am J Physiol Heart Circ Physiol H1671-8 (Pubitemid 30395581)
53. Antoons G, Oros A, Beekman JD, Engelen MA, Houtman MJ, Belardinelli L, Stengl M, Vos MA. Late Na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J Am Coll Cardiol. 2010;55:801-9.
54. Wu L, Shryock J, Song Y, Belardinelli L. An increase in late sodium current potentiates the proarrhythmic activities of lowrisk QT-prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther. 2006;316:718-26. (Pubitemid 43130999)
55. Murdock DK, Kersten M, Kaliebe J, Larrain G. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J. 2009;9:260-7.
56. Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J. 2008;8:175-81.
57. Miles RH, Murdock DK. Ranolazine verses amiodarone for prophylaxis against atrial fibrillation following coronary artery bypass surgery. Heart Rhythm. 2010;7:258.
58. Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol. 1995;6:920-36.
59. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116:1449-57. (Pubitemid 47480635)
60. Rajamani S, Shryock JC, Belardinelli L. Block of tetrodotoxinsensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine. Channels (Austin). 2008;2:449-60.
61. Neef S, Dybkova N, Sossalla S, Ort KR, Fluschnik N, Neumann K, Seipelt R, Schondube FA, Hasenfuss G, Maier LS. CaMKIIdependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res. 2010;106:1134-44.
62. Kumar K, Nearing BD, Bartoli CR, Kwaku KF, Belardinelli L, Verrier RL. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart. J Cardiovasc Electrophysiol. 2008;19:1073-9.
63. Kumar K, Nearing BD, Carvas M, Nascimento BC, Acar M, Belardinelli L, Verrier RL. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol. 2009;20:796-802.
64. Carvas M, Nascimento BC, Acar M, Nearing BD, Belardinelli L, Verrier RL. Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart. J Cardiovasc Pharmacol. 2010;55:286-91.
65. Sicouri S, Burashnikov A, Belardinelli L, Antzelevitch C. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol. 2010;3:88-95.
66. BurashnikovA, Sicouri S,DiDiego JM, Belardinelli L, Antzelevitch C. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol. 2010;56:1216-24. The study nicely shows that a combination therapy of ranolazine with dronedarone may be a novel antiarrhythmic approach on which the HARMONY study is based.
67. Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm. 2008;5:1019-26.
68. Mullard A. Second chance for dronedarone after recent setback? Lancet. 2012;379:601.